Novel oral glucose-lowering drugs are associated with lower risk of all-cause mortality, cardiovascular events and severe hypoglycaemia compared with insulin in patients with type 2 diabetes

Aims To investigate the association of novel oral glucose‐lowering drugs ( GLDs ), compared with that of insulin, with risk of all‐cause mortality, cardiovascular disease ( CVD ) and severe hypoglycaemia. Methods During 2013 to 2014 all patients with type 2 diabetes in Sweden identified as new users of novel oral GLDs , either dipeptidyl peptidase‐4 ( DPP ‐4) inhibitors or sodium‐glucose cotransporter‐2 ( SGLT2 ) inhibitors (only dapagliflozin...